The natural immunity to evolutionary atavistic endotoxin for human cancer.
We propose a new theory of the immunological control of cancer corresponding to the hypothesis that the specific natural immunity to evolutionary atavistic endotoxin has a potential role in human cancer prevention. The results of our studies have shown that IgMNAE, i.e. endogenous or spontaneous IgM class antibodies to enterobacterial lipopolysaccharide molecules (lipid A), control the immune mechanisms responsible for the internal medium stability not only against the damaging impact of the carcinogenic factors, but also against the malignant transformation of its own degenerated cells. Among people who in 1979 and 1982 had IgMNAE in their blood serum, after 15-30years fell ill with cancer 10%, versus 15% among people who had no IgMNAE (p<0.05). Therefore, it is possible to maintain that the stimulation of IgMNAE synthesis would help in the destruction and elimination of damaged somatic cells or prevent their mechanisms from the formation of invasiveness, metastatic and other properties of their parasitism. In the mechanism of the natural immunity to endotoxin it is possible to see the formation of the respective evolutionary protective reactions which protect the damaged cells from acquiring resistance to damaging factors and thus from becoming an independent new parasitic population. Thereby the presented theory of the immunological control of cancer has a causal connection with our evolutionary resistance theory of the origin of cancer. Collectively, these data suggest that activation of natural immunity to endotoxin and production of vaccines against evolutionary atavistic endotoxin or gram-negative bacterial endotoxin can be helpful when applied in cancer prophylaxis for persons with a low level of natural immunity to endotoxin and perhaps in creating immunotherapeutic methods for stopping the endogenous parasitism of tumour cells by binding IgMNAE to atavistic endotoxin in cancer patients.
Center of Scientific Research, Laboratory of Immunology, Lithuanian Cancer Registry, National Cancer Institute, Santariškių Str. 1, LT-08660 Vilnius, Lithuania. Electronic address: ruta.grikienyte@gmail.com.
Elena
E
Moncevičiūtė-Eringienė
Center of Scientific Research, Laboratory of Immunology, Lithuanian Cancer Registry, National Cancer Institute, Santariškių Str. 1, LT-08660 Vilnius, Lithuania.
Kristina
K
Rotkevič
Center of Scientific Research, Laboratory of Immunology, Lithuanian Cancer Registry, National Cancer Institute, Santariškių Str. 1, LT-08660 Vilnius, Lithuania.
Ruta Grikienyte
RG
Grikienis
D005075:Biological Evolution; D004731:Endotoxins / Q000633:toxicity*; D006801:Humans; D007109:Immunity; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology
D004731:Endotoxins